The National Institute for Health and Clinical Excellence single technology appraisal process: Lessons from the first 4 years

Value in Health

Volumn 14, Issue 8, 2011, Pages 1158-1165

  Kaltenthaler, Eva ^a   Papaioannou, Diana ^a   Boland, Angela ^b   Dickson, Rumona ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

critique; data collection; decision making; health care decision making; United Kingdom

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; HEALTH CARE POLICY; INTERNET; PRIORITY JOURNAL; TECHNOLOGY; UNITED KINGDOM;

BIOMEDICAL TECHNOLOGY; COST-BENEFIT ANALYSIS; DECISION MAKING; GREAT BRITAIN; HUMANS; INTERNET; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TIME FACTORS;

EID: 82955205828     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.06.007     Document Type: Article

References (36)

1. National Institute for Health and Clinical Excellence Guide to the single technology appraisal process http://www.nice.org.uk/media/913/06/Guide-to-the- STA-proof-6-26-10-09.pdf October 2009 [Accessed July 6, 2011]
2. F. Walsh Revolutionary cancer drug arrives in the UK November 2, 1999 BBC News http://news.bbc.co.uk/1/hi/health/503245.stm [Accessed July 6, 2011]
3. J. Meikle Judge orders health trust to fund interim course of Herceptin for cancer patient December 22, 2005 The Guardian http://www.guardian.co.uk/ society/2005/dec/22/cancercare.health [Accessed July 6, 2011]
4. M.J. Buxton, R. Akehurst How NICE is the UK's fast-track system? Scrip Mag 2006 24 25 XX
5. E. Kaltenthaler, P. Tappenden, A. Booth, R. Akehurst Comparing methods for full versus single technology appraisal: a case study of docetaxel and paclitaxel for early breast cancer Health Pol 87 2008 389 400
6. L. Barham Single technology appraisals by NICE: are they delivering faster guidance to the NHS? Pharmacoeconomics 26 2008 1037 1043
7. A. Wailoo, C. Pickstone A review of the NICE single technology appraisal process http://www.nice.org.uk/media/6A6/0A/STAReviewReport.pdf January 23, 2008 [Accessed July 6, 2011]
8. National Institute for Health and Clinical Excellence DSU review of the single technology appraisal process Board Report http://www.nice.org.uk/media/ 6A5/EC/STAReviewBoardCoverPaper.pdf March 19, 2008 [Accessed July 6, 2011]
9. National Institute for Health and Clinical Excellence Guide to the single technology appraisal (STA) process (2006) http://www.nice.org.uk/aboutnice/ howwework/devnicetech/technologyappraisalprocessguides/ singletechnologyappraisalsprocess/single-technology-appraisals-process.jsp? domedia=1&mid=8DE6BB4B-19B9-E0B5-D4171540D253951B January 18, 2008 [Accessed July 6, 2011]
10. National Institute for Health and Clinical Excellence Guide to the methods of technology appraisal http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf June 2008 [Accessed July 6, 2011]
11. National Institute for Health and Clinical Excellence NICE welcomes topic selection consultation [press release] http://www.nice.org.uk/niceMedia/pdf/ 2006-10-topic-selection.pdf March 6, 2006 [Accessed July 6, 2011]
12. E. Kaltenthaler, A. Boland, C. Carroll Evidence review group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis Health Technol Assess 15 2011 1 82
13. National Institute for Health and Clinical Excellence NICE guidance by topic http://www.nice.org.uk/Guidance/Topic July 7, 2011 [Accessed July 7, 2011]
14. National Institute for Health and Clinical Excellence Rimonabant for the treatment of overwight and obese patients http://www.nice.org.uk/guidance/index. jsp?action=byId&o=11738&history=t March 30, 2010 [Accessed July 6, 2011]
15. National Institute for Health and Clinical Excellence Natalizumab for the treatment of multiple sclerosis http://www.nice.org.uk/guidance/index.jsp? action=byId&o=11701&history=t March 30, 2010 [Accessed July 6, 2011]
16. National Institute for Health and Clinical Excellence Lung cancer (non-small cell) - pemetrexed: final appraisal determination http://www.nice.org.uk/guidance/index.jsp?action=download&o=35192 February 15, 2007 [Accessed July 7, 2011]
17. National Institute for Health and Clinical Excellence Lung cancer (non-small cell, first lline treatment) - pemetrexed: evidence review group report http://www.nice.org.uk/guidance/index.jsp?action=download&o=43758 April 15, 2009 [Accessed July 7, 2011]
18. National Institute for Health and Clinical Excellence Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (review of technology appraisal guidance 37) http://guidance.nice.org. uk/index.jsp?action=byId&o=11730&history=t March 30, 2010 [Accessed July 7, 2011]
19. National Institute for Health and Clinical Excellence 2000/030 Summary of the appeals process http://www.nice.org.uk/newsroom/pressreleases/ pressreleasearchive/pressreleases2000/2000-030-summary-of-the-appeals-process. jsp August 24, 2000 [Accessed July 7, 2011]
20. National Institute for Health and Clinical Excellence Cetuximab for the treatment of head and neck cancer http://www.nice.org.uk/guidance/index.jsp? action=byId&o=11697&history=t March 30, 2010 [Accessed July 7, 2011]
21. National Institute for Health and Clinical Excellence Febuxostat for the management of hyperuricaemia in patients with gout http://www.nice.org.uk/ guidance/index.jsp?action=byId&o=11830&history=t April 14, 2011 [Accessed July 7, 2011]
22. National Institute for Health and Clinical Excellence Rituximab for the treatment of relapsed chronic lymphocytic leukaemia http://guidance.nice.org.uk/ TA/Wave18/23 July 28, 2010 [Accessed July 7, 2011]
23. National Institute for Health and Clinical Excellence Lung cancer (non-small cell) - erlotinib http://guidance.nice.org.uk/TA/Wave2/5 March 30, 2010 [Acccessed July 7, 2011]
24. National Institute for Health and Clinical Excellence Pemetrexed for the treatment of non-small cell lung cancer http://www.nice.org.uk/guidance/index. jsp?action=byId&o=11715&history=t March 30, 2010 [Accessed July 7, 2011]
25. National Institute for Health and Clinical Excellence Bortezomib monotherapy for relapsed multiple myeloma http://www.nice.org.uk/guidance/index. jsp?action=byId&o=11713&history=t March 30, 2010 [Accessed July 7, 2011]
26. National Institute for Health and Clinical Excellence Breast cancer (early) - trastuzumab http://www.nice.org.uk/guidance/index.jsp?action= byId&o=11585&history=t March 30, 2010 [Accessed July 7, 2011]
27. National Institute for Health and Clinical Excellence Abatacept for the treatment of rheumatoid arthritis http://www.nice.org.uk/guidance/index.jsp? action=byId&o=11720&history=t March 30, 2010 [Accessed July 7, 2011]
28. National Institute for Health and Clinical Excellence Sorafenib for advanced hepatocelluar carcinoma http://guidance.nice.org.uk/TA/Wave17/8 May 27, 2010 [Accessed July 7, 2011]
29. National Institute for Health and Clinical Excellence Appraising end of life medicines http://www.nice.org.uk/newsroom/features/ endoflifemedicinesconsultation.jsp July 12, 2010 [Accessed July 7, 2011]
30. National Institute for Health and Clinical Excellence Erlotinib for the treatment of non-small cell lung cancer http://guidance.nice.org.uk/TA162 July 4, 2011 [Accessed July 7, 2011]
31. F.M. Clement, A. Harris, J.J. Li Using effectiveness and cost-effectiveness to make drug coverage decisions A comparison of Britain, Australia, and Canada JAMA 302 2009 1437 1443
32. National Institute for Health and Clinical Excellence Erlotinib monotherapy for the maintenance treatment of non-small-cell lung cancer http://guidance.nice.org.uk/TA/Wave19/55 June 29, 2011 [Accessed July 7, 2011]
33. A. Haycox Does "NICE blight" exist, and if so, why? Pharmacoeconomics 26 2008 987 989
34. M. Drummond, C. Sorenson Can NICE be nicer? In a world of budget constraints there are no wasy solutions Value Health 12 2009 634 636
35. M. Barbieri, N. Hawkins, M. Sculpher Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies Value Health 12 2009 193 201
36. C.M. Bell, D.R. Urbach, J.G. Ray Bias in published cost effectiveness studies: systematic review BMJ 332 2006 699 703